Business Context and Reporting Period
Company: Omega Healthcare Investors, Inc. (OHI)
Filing Type: Form 8-K (Current Report)
Date of Report: November 3, 2025
Event: The Company entered into a new "at-the-market" equity offering sales agreement and terminated its prior agreement dated September 6, 2024.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a new financing facility.
- Maximum Aggregate Gross Sales Price: $2,000,000,000 (2 billion USD) for Issuance Shares and Forward Shares combined.
- Compensation to Sales Agents: Up to 2.0% of the gross sales price of Issuance Shares.
- Compensation to Forward Sellers: Up to 2.0% of the gross sales price of Forward Shares (via reduced initial forward sale price).
Material Changes
The primary material change is the execution of a new Sales Agreement on November 3, 2025, which supersedes the previous "at-the-market" equity offering sales agreement dated September 6, 2024. The new agreement expands the scope to include both direct issuance of shares and forward sale agreements.
Guidance, Outlook, and Risks
Management Commentary: The Company has no obligation to sell any securities under the agreement and may suspend solicitation at any time. Sales will be made at prevailing market prices or negotiated prices.
Settlement Terms and Risks:
- Physical Settlement: The Company expects to physically settle forward sale agreements by delivering shares and receiving proceeds within two years of entry.
- Cash Settlement Risk: If the Company elects cash settlement, it may receive no proceeds and may owe cash to Forward Purchasers.
- Net Share Settlement Risk: If the Company elects net share settlement, it will receive no proceeds and may owe shares to Forward Purchasers.
- Early Termination: Forward sale agreements are subject to early termination or settlement under certain circumstances.
Related Party Transactions: Sales Agents and Forward Purchasers may engage in other commercial dealings with the Company for which they receive fees.
Investor Verification Checklist
- Verify the specific terms of the Sales Agreement filed as Exhibit 1.1.
- Review the form of forward sales agreement filed as Annex 2 to Exhibit 1.1 for settlement conditions.
- Monitor future filings for actual sales volumes and proceeds received under the $2 billion facility.
- Assess the impact of potential cash or net share settlements on future cash flow and share count.
- Confirm the list of participating Sales Agents and Forward Purchasers for potential conflicts of interest.